leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...114115116117118119120121122123124...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Venous thromboembolism (VTE) in pancreatic cancer patients – single centre experience ([VIRTUAL]) -  Nov 16, 2021 - Abstract #NCRI2021NCRI_291;    
    30% of patients in the audit who developed VTE were on Gemcitabine alone, 28% were on Gemcitabine based combination chemotherapy, and 18% were on the FOLFIRINOX regimen...We now routinely include thromboprophylaxis for all pancreatic cancer patients who are on chemotherapy unless contraindicated. Impact statement Thromboprophylaxis may reduce the risk of life threatening venous thrombo-embolic events and complications in pancreatic cancer patients undergoing chemotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
    Clinical, Journal:  A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome (Pubmed Central) -  Nov 16, 2021   
    However, local recurrence was noted, and the tumor increased even after CapeOX plus bevacizumab and fluorouracil plus leucovorin plus irinotecan plus panitumumab (FOLFIRI plus panitumumab). Pembrolizumab was administered after confirming high-frequency microsatellite instability, and the tumor shrank markedly and remained shrunk for 20 months.
  • ||||||||||  irinotecan / Generic mfg.
    Review, Journal:  Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. (Pubmed Central) -  Nov 12, 2021   
    Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX (FOLinic acid, 5-Fluroruracil, IRINotecan, and Oxaliplatin) significantly improve patient survival, the prevalence of therapy resistance remains a major roadblock in the success of these agents...Specifically, we have discussed the metabolic alterations and DNA repair mechanisms observed in PDAC and current approaches in targeting these mechanisms. Our discussion also includes the lessons learned following the failure of immunotherapy in PDAC and current approaches underway to improve tumor's immunological response.
  • ||||||||||  numidargistat (INCB001158) / Calithera
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) -  Nov 12, 2021   
    P1/2,  N=149, Active, not recruiting, 
    Our discussion also includes the lessons learned following the failure of immunotherapy in PDAC and current approaches underway to improve tumor's immunological response. Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Preclinical, Journal:  The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. (Pubmed Central) -  Nov 12, 2021   
    An analysis of cell viability, proliferation, and cell cycle demonstrated that CAP in combination with FOLFIRINOX is more effective than either treatment alone at a lower FOLFIRINOX dose of 6.7 µM fluorouracil, 1.7 µM leucovorin, 0.6 µM irinotecan, and 0.5 µM oxaliplatin and a shorter CAP treatment of 1, 3, or 5 min. In conclusion, CAP has the potential to reduce the toxicity burden of FOLFIRINOX and warrants further investigation as an adjuvant therapy.
  • ||||||||||  Biomarker, Enrollment change, Trial withdrawal:  Neoadjuvant Therapy for Localized Rectal Adenocarcinoma (clinicaltrials.gov) -  Nov 10, 2021   
    P2,  N=0, Withdrawn, 
    This result is not only consistent with a recent study suggesting the immunosuppressive effect of mutant KRAS but also provides insight into the type-specific prognostic effect of KRAS mutations. N=45 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    A Rheumatologist’s nightmare () -  Nov 7, 2021 - Abstract #APLAR2021APLAR_509;    
    She was admitted to hospital and was started on intravenous saline drip, antibiotics and intravenous folinic acid while waiting for TDM of methotrexate level. Share decision making, communication and care delivery practices is of upmost importance in exploring patient and caregiver understanding before drug prescription to prevent harm.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal:  Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. (Pubmed Central) -  Nov 6, 2021   
    In this small series, we suggest that single-agent and combined-modality neoadjuvant immunotherapy/chemotherapy appear to be safe and effective treatment options for patients with (dMMR) locally advanced rectal cancer. Our findings encourage further studies to investigate the role of neoadjuvant immunotherapy as a viable treatment strategy in this population.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Metastases:  NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) -  Nov 5, 2021   
    P2,  N=44, Recruiting, 
    The results of this study will provide valuable data regarding who is at highest risk for AEs and can be used to tailor supportive care during this potentially toxic chemotherapy. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Fluorouracil Bolus Use in Infusional Regimens Among Oncologists-A Survey by Brazilian Group of Gastrointestinal Tumors. (Pubmed Central) -  Nov 4, 2021   
    These studies are intended to provide Level 1 clinical evidence and real-world data demonstrating the clinical utility and safety of the use of IRE in combination with chemotherapy in patients with Stage 3 PDAC. Our survey indicates that experience in oncology practice and percentage of time dedicated to treat GI cancers influence the prescription of 5-FU bolus in Brazil, with more frequent omission of it among experienced gastrointestinal specialists, particularly in the metastatic setting.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) -  Nov 3, 2021   
    P2,  N=138, Active, not recruiting, 
    CONCLUSIONS This report shows that the PIPAC procedure is reproducible elsewhere, with safety and good functional results. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  leucovorin calcium / Generic mfg.
    PERSISTENT MTHFD1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY DESPITE FOLINIC ACID SUPPLEMENTATION; HEMATOPOIETIC ALLOGENEIC TRANSPLANTATION REQUIRED (Hall B (1st Floor); Monitor 05) -  Nov 2, 2021 - Abstract #ACAAI2021ACAAI_827;    
    The patient developed hyperhomocysteinemia, hypertension and proteinuria at four weeks of life; these resolved soon after starting folinic acid, hydroxocobalamin, and betaine...Due to CMV viremia and lack of immunological improvement, the patient received a T cell-depleted haploidentical hematopoietic cell transplant (HCT) after low-exposure busulfan-based conditioning...He has normal developmental milestones, but persistent anemia of unclear cause with a normal bone marrow histology. Discussion This is the first description of MTHFD1-deficient SCID without T cell development after folinic acid therapy requiring hematopoietic allogeneic transplantation.